Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | LSS | P48449 | 3/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24042812 | 0.91 | MAPT (0.40) | TSHRMAPTCA12CA1CA2 | |
| SCHEMBL22256857 | 0.85 | TSHR (0.44) | TSHRMAPTCA12CA1CA2 | |
| SCHEMBL17872849 | 0.85 | ALDH1A1 (0.36) | TSHRMAPTLSSCA12CA1 | |
| SCHEMBL17872847 | 0.85 | ALDH1A1 (0.36) | TSHRMAPTLSSCA12CA1 | |
| SCHEMBL12549046 | 0.84 | JAK3 (0.37) | TSHRMAPTCA12CA1CA2 | |
| SCHEMBL12548499 | 0.84 | JAK3 (0.37) | TSHRMAPTCA12CA1CA2 | |
| SCHEMBL12712977 | 0.84 | JAK3 (0.37) | TSHRMAPTCA12CA1CA2 | |
| SCHEMBL22256852 | 0.83 | TSHR (0.47) | TSHRMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL12548917 | 0.82 | TSHR (0.35) | TSHRMAPTCA12CA1CA2 | |
| SCHEMBL12548922 | 0.82 | TSHR (0.35) | TSHRMAPTCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4069240-A | GROUP 8 METAL CATALYST | UNIROYAL, INC. (US) | 1978-01-17 | — | — | US | claimed |
| US-8809574-B2 | Method for preparing isocyanates by liquid-phase thermal cracking | LANZHOU INSTITUTE OF CHEMICAL PHYSICS, CHINESE ACADEMY OF SCIENCES (CN) | 2014-08-19 | — | — | US | disclosed |
| US-20110021810-A1 | METHOD FOR PREPARING ISOCYANATES BY LIQUID-PHASE THERMAL CRACKING | LANZHOU INSTITUTE OF CHEMICAL PHYSICS, CHINESE ACADEMY OF SCIENCES (CN) | 2011-01-27 | — | — | US | disclosed |
| US-4069240-A | GROUP 8 METAL CATALYST | UNIROYAL, INC. (US) | 1978-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021810-A1 | METHOD FOR PREPARING ISOCYANATES BY LIQUID-PHASE THERMAL CRACKING | DBI, CCNI, DGKI | TSHR 4586/4885MAPT 3168/4885LSS 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.